• 1. An alkynylboronatecycloaddition strategy to functionalised benzyne derivatives?
  James D. Kirkham,Patrick M. Delaney,George J. Ellames,Eleanor C. Row,Joseph P. A. Harrity Chem. Commun., 2010,46, 5154-5156
• 2. An approach towards the synthesis of novel fused nitrogen tricyclic heterocyclic scaffolds via GBB reaction?
  Sandip Gangadhar Balwe,Yeon Tae Jeong Org. Biomol. Chem., 2018,16, 1287-1296
• 3. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 4. An investigation of the electrochemical delithiation process of carbon coated α-Fe2O3nanoparticles
  Adrian Brandt,Florian Winter,Sebastian Klamor,Frank Berkemeier,Jatinkumar Rana,Rainer P?ttgen,Andrea Balducci J. Mater. Chem. A, 2013,1, 11229-11236
• 5. An inter-tangled network of redox-active and conducting polymers as a cathode for ultrafast rechargeable batteries
  Jieun Kim,Han-Saem Park,Tae-Hee Kim,Sung Yeol Kim,Hyun-Kon Song Phys. Chem. Chem. Phys., 2014,16, 5295-5300

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Primary amines

Professional Introduction to Amantadine-d (CAS No. 33830-10-3)

Amantadine-d, a compound with the chemical identifier CAS No. 33830-10-3, represents a significant advancement in the field of pharmaceutical chemistry and biomedicine. This compound, derived from the broader class of antiviral agents, has garnered considerable attention due to its unique pharmacological properties and potential applications in addressing various health challenges. The molecular structure of Amantadine-d incorporates specific functional groups that contribute to its distinct mechanism of action, making it a subject of intense research interest.

The pharmacological profile of Amantadine-d is characterized by its ability to interact with biological targets in a manner that disrupts viral replication processes. This interaction is particularly relevant in the context of infections caused by viruses that rely on specific cellular pathways for their propagation. Recent studies have highlighted the compound's efficacy against certain viral strains, underscoring its potential as a therapeutic agent in the management of infectious diseases.

One of the most compelling aspects of Amantadine-d is its versatility in modulating cellular responses. Research has demonstrated that this compound can influence multiple signaling pathways, which not only aids in its antiviral effects but also suggests possible applications in other therapeutic areas such as neurodegenerative disorders. The ability of Amantadine-d to cross the blood-brain barrier has opened new avenues for investigating its role in conditions like Parkinson's disease, where modulation of dopamine pathways is crucial.

In recent years, the development of novel drug candidates has been accelerated by advancements in computational chemistry and high-throughput screening techniques. These technologies have enabled researchers to rapidly identify and optimize compounds like Amantadine-d for enhanced efficacy and reduced side effects. The integration of machine learning algorithms into drug discovery processes has further streamlined the identification of potential therapeutic targets, making compounds such as Amantadine-d more accessible for clinical development.

The synthesis and characterization of Amantadine-d have been subjects of extensive investigation. The chemical synthesis involves multi-step reactions that require precise control over reaction conditions to ensure high yield and purity. Analytical techniques such as nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS), and X-ray crystallography have been instrumental in elucidating the molecular structure and confirming the identity of Amantadine-d.

From a clinical perspective, the potential applications of Amantadine-d extend beyond antiviral therapy. Preliminary clinical trials have suggested that this compound may have beneficial effects in treating symptoms associated with chronic fatigue syndrome and fibromyalgia. The mechanisms underlying these effects are still under investigation, but they likely involve interactions with adrenergic receptors and modulation of neurotransmitter release.

The safety profile of Amantadine-d is another critical area of focus. While generally well-tolerated, some studies have reported mild side effects such as nausea and dizziness. However, these effects are often transient and manageable with dose adjustments or supportive care. Ongoing research aims to further refine dosing regimens and explore strategies to minimize adverse reactions, ensuring that Amantadine-d can be safely integrated into therapeutic protocols.

The regulatory landscape for Amantadine-d is evolving alongside advancements in pharmaceutical science. Regulatory agencies worldwide are increasingly recognizing the importance of innovative approaches to drug development, including accelerated approval pathways for treatments targeting unmet medical needs. This evolving framework provides opportunities for companies developing compounds like Amantadine-d to bring new therapies to market more efficiently.

Future directions in the study of Amantadine-d include exploring its potential as an adjuvant therapy in combination with other treatments for viral infections and chronic conditions. The concept of combination therapy leverages the synergistic effects of multiple agents to enhance treatment outcomes while potentially reducing the risk of resistance development. Additionally, research into novel derivatives of Amantadine-d may uncover additional pharmacological properties that could expand its therapeutic utility.

The role of interdisciplinary collaboration in advancing pharmaceutical research cannot be overstated. The development of compounds like Amantadine-d benefits from the expertise of chemists, biologists, pharmacologists, and clinicians working together to address complex health challenges. Such collaborations foster innovation and accelerate the translation of laboratory discoveries into tangible therapeutic benefits for patients.

In conclusion, Amantadine-d (CAS No. 33830-10-3) represents a promising advancement in pharmaceutical chemistry with significant implications for antiviral therapy and beyond. Its unique molecular properties, combined with ongoing research efforts aimed at optimizing its efficacy and safety, position it as a compound worthy of continued investigation and clinical development. As our understanding of biological systems grows more sophisticated, so too does our capacity to develop innovative treatments like Amantadine-d that address some of humanity's most pressing health challenges.

• 383185-93-1(Cyclohexanamine, 1,3-dimethyl-, (1R,3R)-rel- (9CI))
• 68288-34-6(1-propylcyclohexan-1-amine)
• 6526-78-9(Cyclohexanamine,1-methyl-)
• 768-94-5(Amantadine)
• 383186-00-3(Cyclohexanamine, 1,3-dimethyl-, (1R,3S)-rel- (9CI))
• 1193-42-6(Bicyclo[2.2.2]octan-1-amine)
• 3048-63-3(Tricyclo4.3.1.1~3,8~undec-3-ylamine)
• 2626-60-0(1-ethylcyclohexan-1-amine)
• 40933-03-7(Tricyclo[3.3.1.13,7]decan-1-amine-d2(9CI))
• 1219805-53-4(1-Aminoadamantane-2,2,2′,2′,2″,2″-d6)